EXEL - exelixis.com Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Exelixis, Inc. (EXEL)

An active R&D stage and the launch of new drugs are driving the P/E balance and growth dynamics, where the data sequence on the GURU.Markets chart confirms the investment attractiveness of Exelixis, Inc. (EXEL). The value of 0.91 shows the current magnitude of the metric. The company's foundation relies on physician confidence in targeted therapy and strict adherence to environmental standards for chemical waste disposal.

EXEL: exelixis.com Price/Earnings to Growth Multiple 07/04/2022 - 11/10/2026

Metric breakdowns and analytics for Exelixis, Inc. (EXEL)

- market value and analyst target forecast:
Price Rate Chart Exelixis Inc|EXEL - Consensus Target
- market capitalization statistics:
Market Value Exelixis Corp|EXEL - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value of a Share Exelixis|EXEL - Company Net Assets|Market Cap to Book Value Multiple exelixis.com|EXEL - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Exelixis, Inc.|EXEL - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital exelixis.com|EXEL - Company Aggregate Debts|Debt to Net Assets Exelixis Corp|EXEL - Company Long-Term Debts|Short-Term Debt Exelixis|Intermediate Liquidity Ratio exelixis.com
- earnings and valuation multiples information:
EXEL - Net Profit|Expected Net Profit Exelixis, Inc.|EXEL - P/E Multiple|Price to Future Earnings Ratio Exelixis Inc.|EXEL - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Exelixis Corp|EXEL - Operating profit before deduction of amortization|Earnings per share for the last four quarters Exelixis|EXEL - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months exelixis.com|EXEL - Earnings growth in current year|Expected net earnings per share growth next year Exelixis, Inc.
General company analysis:Exelixis, Inc.
Signature product of exelixis.com

The development of targeted cancer therapies at Exelixis, Inc. (EXEL) is protected by humanitarian status, which minimizes geopolitical risks and stabilizes the company's PEG ratio. This indicator divides the P/E ratio by the annual earnings growth rate, allowing investors to determine if they are overpaying for business momentum: values below one signal that the asset is fundamentally undervalued relative to its expansion.

Competing companies

Genmab AS (GMAB) - Price to Net Income Growth Ratio|Nuvalent Corp - Price/Earnings to Growth Multiple|Kymera Corp (KYMR) - Price to Earnings Adjusted for Growth Rate|IDYA: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ELVN (enliventherapeutics.com)|ORIC (ORIC Pharmaceuticals, Inc.) - Price/Earnings to Growth Multiple|RLAY: Company Value to Earnings Growth Ratio|NRIX (Nurix Pharma) - PEG Multiple|PEG Multiple Tyra Corp|Price/Earnings to Growth Ratio Verastem, Inc. (VSTM)|GLUE (monterosatx.com) - Growth-Adjusted Payback Ratio|PEG Multiple CGEM (Cullinan Therapeutics, Inc.)|Price to Net Income Growth Ratio Immuneering Corp|C4 Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate Black Diamond Therapeutics, Inc|RPTX (Repare Therapeutics) - Price/Earnings to Growth Multiple|PMVP: Company Value to Earnings Growth Ratio|KPTI (Karyopharm Therapeutics, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Propanc Biopharma, Inc. PPCB|PEG Multiple BGMS|aadibio.com - Growth-Adjusted P/E Ratio|Aileron Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio BPMC|GLYC: Price/Earnings to Growth Multiple|SpringWorks Therapeutics Inc. - Company Value to Earnings Growth Ratio